228 related articles for article (PubMed ID: 26356271)
1. Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway.
Xia C; Bai X; Hou X; Gou X; Wang Y; Zeng H; Huang M; Jin J
Cell Physiol Biochem; 2015; 37(2):816-24. PubMed ID: 26356271
[TBL] [Abstract][Full Text] [Related]
2. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
4. 3',4',5',5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway.
Hou X; Bai X; Gou X; Zeng H; Xia C; Zhuang W; Chen X; Zhao Z; Huang M; Jin J
Mol Cells; 2015 May; 38(5):396-401. PubMed ID: 25843086
[TBL] [Abstract][Full Text] [Related]
5. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
6. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
7. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of FTY720 and cisplatin exhibits enhanced antitumour effects on cisplatin-resistant non-small lung cancer cells.
Li Y; Hu T; Chen T; Yang T; Ren H; Chen M
Oncol Rep; 2018 Feb; 39(2):565-572. PubMed ID: 29207165
[TBL] [Abstract][Full Text] [Related]
9. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
10. β-elemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway.
Yao CC; Tu YR; Jiang J; Ye SF; Du HX; Zhang Y
Oncol Rep; 2014 May; 31(5):2131-8. PubMed ID: 24627125
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
12. [Wogonoside reverses cisplatin resistance in SGC7901/cDDP cells through inhibition of PI3K/Akt/Nrf2/ARE signaling pathway].
Wang LJ; Wang SG; Deng TX
Sheng Li Xue Bao; 2018 Aug; 70(4):397-405. PubMed ID: 30112565
[TBL] [Abstract][Full Text] [Related]
13. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
14. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
He R; Liu H
Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
[TBL] [Abstract][Full Text] [Related]
15. Salvianolic acid A reverses cisplatin resistance in lung cancer A549 cells by targeting c-met and attenuating Akt/mTOR pathway.
Tang XL; Yan L; Zhu L; Jiao DM; Chen J; Chen QY
J Pharmacol Sci; 2017 Sep; 135(1):1-7. PubMed ID: 28939129
[TBL] [Abstract][Full Text] [Related]
16. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
[TBL] [Abstract][Full Text] [Related]
19. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
20. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
Zhang L; Liu X; Tang Z; Li X; Wang G
Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
